Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

EEG Prediction and Clinical Efficacy of tDCS in Fibromyalgia.

NCT: NCT07583056 · NOT_YET_RECRUITING

NCT IDNCT07583056
StatusNOT_YET_RECRUITING
Start Date2026-05-15
Completion2028-06-30

Brief Summary

The purpose of this randomized controlled trial is to investigate the non-inferiority, and possible superiority, of a high-dose home-based tDCS protocol compared with a conventional home-based protocol, and to assess its cost-effectiveness, in patients with fibromyalgia. As complementary goals, we aim to assess the predictive value of baseline EEG for clinical response to high-dose home-based tDCS treatment; and to describe the effectiveness of a high-dose home-based protocol applied to the motor cortex (M1) versus the dorsolateral prefrontal cortex (DLFPC) in patients with fibromyalgia.

Frequently Asked Questions

What is EEG Prediction and Clinical Efficacy of tDCS in Fibromyalgia.?

EEG Prediction and Clinical Efficacy of tDCS in Fibromyalgia. is a clinical trial registered under NCT07583056. Current status: NOT_YET_RECRUITING.

What is the status of NCT07583056?

The current status of NCT07583056 (EEG Prediction and Clinical Efficacy of tDCS in Fibromyalgia.) is: NOT_YET_RECRUITING.

When did EEG Prediction and Clinical Efficacy of tDCS in Fibromyalgia. start?

EEG Prediction and Clinical Efficacy of tDCS in Fibromyalgia. started on 2026-05-15.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.